CL2008000029A1 - Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. - Google Patents

Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.

Info

Publication number: CL2008000029A1
Authority: CL; Chile
Prior art keywords: compounds; bencil; imidazol; inhibitors; pharmaceutical composition
Prior art date: 2007-01-05

Application number

CL200800029A

Other languages

English (en)

Inventor

Rustum Boyce

Eric Martin

Weibo Wang

Hong Yang

Paul A Barsanti

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-05

Filing date

2008-01-04

Publication date

2008-04-04

2008-01-04 Application filed by Novartis Ag filed Critical Novartis Ag

2008-04-04 Publication of CL2008000029A1 publication Critical patent/CL2008000029A1/es

Links

150000001875 compounds Chemical class 0.000 title 2
RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

CL200800029A 2007-01-05 2008-01-04 Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. CL2008000029A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US88374007P	2007-01-05	2007-01-05

Publications (1)

Publication Number	Publication Date
CL2008000029A1 true CL2008000029A1 (es)	2008-04-04

Family

ID=39577804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200800029A CL2008000029A1 (es)	2007-01-05	2008-01-04	Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.

Country Status (30)

Country	Link
US (3)	US7820646B2 (es)
EP (1)	EP2106399A2 (es)
JP (1)	JP2010515687A (es)
KR (1)	KR20090097210A (es)
CN (1)	CN101622247A (es)
AR (1)	AR064760A1 (es)
AU (1)	AU2008205169B2 (es)
BR (1)	BRPI0806264A2 (es)
CA (1)	CA2674318A1 (es)
CL (1)	CL2008000029A1 (es)
CO (1)	CO6561828A2 (es)
CR (1)	CR10879A (es)
DO (1)	DOP2009000169A (es)
EA (1)	EA200900924A1 (es)
EC (1)	ECSP099485A (es)
GE (1)	GEP20125415B (es)
GT (1)	GT200900192A (es)
HN (1)	HN2009001262A (es)
MA (1)	MA31080B1 (es)
MX (1)	MX2009007260A (es)
NI (1)	NI200900134A (es)
NZ (1)	NZ577727A (es)
PE (1)	PE20081850A1 (es)
SM (1)	SMP200900065B (es)
SV (1)	SV2009003325A (es)
TN (1)	TN2009000287A1 (es)
TW (1)	TW200836722A (es)
UA (1)	UA97821C2 (es)
WO (1)	WO2008086122A2 (es)
ZA (1)	ZA200904175B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8252832B2 (en)	2007-12-14	2012-08-28	Novartis Ag	Kinesin inhibitors as cancer therapeutics
KR20130100056A (ko)	2010-04-15	2013-09-09	노파르티스 아게	Ｋｓｐ 억제제로서의 트리아졸 화합물
CN103153970A (zh) *	2010-04-15	2013-06-12	诺瓦提斯公司	作为ksp抑制剂的*唑和噻唑化合物
EP2390247A1 (en) *	2010-05-26	2011-11-30	Netherlands Organisation for Scientific Research (Advanced Chemical Technologies for Sustainability)	Preparation of caprolactone, caprolactam, 2,5-tetrahydrofuran dimethanol, 1,6-hexanediol or 1,2,6-hexanetriol from 5-hydroxymethyl-2-furfuraldehyde
GB201113538D0 (en)	2011-08-04	2011-09-21	Karobio Ab	Novel estrogen receptor ligands
EP2968591A1 (en) *	2013-03-15	2016-01-20	Novartis AG	Cell proliferation inhibitors and conjugates thereof
US9498540B2 (en)	2013-03-15	2016-11-22	Novartis Ag	Cell proliferation inhibitors and conjugates thereof
BR112016014830A2 (pt) *	2013-12-23	2017-09-19	Bayer Pharma AG	Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
SG10201908685QA (en) *	2015-06-22	2019-10-30	Bayer Pharma AG	Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN105330657B (zh) *	2015-12-08	2019-05-21	华润双鹤药业股份有限公司	5-氯-2-[5-(r)-甲基-1,4-二氮杂环庚烷-1-]苯并恶唑的制备方法
CN105367506B (zh) *	2015-12-08	2021-02-05	华润双鹤药业股份有限公司	手性高哌嗪环的制备方法
US11001636B2 (en)	2016-06-15	2021-05-11	Bayer Pharma Aktiengesellschaft	Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
CA3047522A1 (en)	2016-12-21	2018-06-28	Bayer Pharma Aktiengesellschaft	Specific antibody drug conjugates (adcs) having ksp inhibitors
CA3047489A1 (en)	2016-12-21	2018-06-28	Bayer Pharma Aktiengesellschaft	Antibody drug conjugates (adcs) having enzymatically cleavable groups
CN112601553A (zh)	2018-06-18	2021-04-02	拜耳股份有限公司	具有可酶切的接头和改善的活性谱的针对cxcr5的结合剂-药物缀合物

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2550959C3 (de) *	1975-11-13	1980-12-04	Hoechst Ag, 6000 Frankfurt	Tetrazolyl-imidazole und Tetrazolyl--benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4235871A (en) *	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) *	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
GB2157285B (en)	1984-04-11	1987-10-28	Erba Farmitalia	1h, 7h-pyrazolo1, 5-a pyrimidine-7-one derivatives and process for their preparation
US5023252A (en) *	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US4837028A (en) *	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5011472A (en) *	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
US5859012A (en) *	1996-04-03	1999-01-12	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
WO1998027108A2 (en)	1996-12-16	1998-06-25	Fujisawa Pharmaceutical Co., Ltd.	New amide compounds and their use as nitric oxide synthase inhibitors
US6117940A (en)	1997-10-17	2000-09-12	Mjalli; Adnan M. M.	Amino-ketone solid support templates
US6172087B1 (en) *	1998-06-03	2001-01-09	Gpi Nil Holding, Inc.	N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
EP1165519A1 (en)	1999-04-02	2002-01-02	Neurogen Corporation	Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6271241B1 (en) *	1999-04-02	2001-08-07	Neurogen Corporation	Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US7291641B2 (en) *	1999-10-11	2007-11-06	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI283577B (en)	1999-10-11	2007-07-11	Sod Conseils Rech Applic	Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US20040132788A1 (en) *	1999-10-11	2004-07-08	Chabrier De Lassauniere Pierre-Etienne	Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US6545004B1 (en)	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
NZ518480A (en)	1999-10-27	2004-02-27	Cytokinetics Inc	Methods and compositions utilizing quinazolinones
US6620882B1 (en)	2000-05-02	2003-09-16	Advanced Syntech, Llc	Solid support template for preparation of highly functionalized heterocycle compounds
US6683191B2 (en)	2000-06-05	2004-01-27	Ortho-Mcneil Pharmaceuticals, Inc.	Method for synthesis of substituted azole libraries
WO2001094318A2 (en)	2000-06-05	2001-12-13	Ortho-Mcneil Pharmaceutical, Inc.	Method for synthesis of substituted azole libraries
CN1444566A (zh)	2000-08-01	2003-09-24	研究及应用科学协会股份有限公司	咪唑基衍生物
AU2001296799A1 (en)	2000-10-06	2002-04-15	Neurogen Corporation	Benzimidazole and indole derivatives as crf receptor modulators
EP1341768A1 (en)	2000-12-07	2003-09-10	AstraZeneca AB	Therapeutic benzimidazole compounds
WO2002083143A1 (en)	2000-12-11	2002-10-24	Tularik Inc.	Cxcr3 antagonists
US20040132830A1 (en)	2001-01-19	2004-07-08	Finer Jeffrey T	Triphenylmethane kinesin inhibitors
EP1360180A1 (en)	2001-01-19	2003-11-12	Cytokinetics, Inc.	Phenothiazine kinesin inhibitors
JP2005511581A (ja)	2001-11-07	2005-04-28	メルク　エンド　カムパニー　インコーポレーテッド	有糸***キネシン阻害剤
US6753428B2 (en)	2001-11-20	2004-06-22	Cytokinetics, Inc.	Process for the racemization of chiral quinazolinones
US7378411B2 (en)	2001-12-06	2008-05-27	Merck & Co., Inc.	Substituted thienopyrimidinones as a mitotic kinesin inhibitor
AU2002363960B2 (en)	2001-12-06	2008-07-10	Merck Sharp & Dohme Corp.	Mitotic kinesin inhibitors
DE60234278D1 (de)	2001-12-06	2009-12-17	Merck & Co Inc	Mitotische kinesin-hemmer
US20050107404A1 (en)	2001-12-06	2005-05-19	Fraley Mark E.	Mitotic kinesin inhibitors
EP1465896A4 (en)	2001-12-06	2006-01-11	Merck & Co Inc	MITOTIC INHIBITORS OF KINESIN
WO2003059289A2 (en)	2002-01-10	2003-07-24	Neurogen Corporation	Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
CA2475879A1 (en)	2002-02-15	2003-08-28	Cytokinetics, Inc.	Synthesis of quinazolinones
ATE448207T1 (de)	2002-03-08	2009-11-15	Merck & Co Inc	Mitotische kinesin-hemmer
DE10211770A1 (de)	2002-03-14	2003-10-02	Boehringer Ingelheim Pharma	Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7026312B2 (en) *	2002-03-14	2006-04-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US6924376B2 (en)	2002-04-17	2005-08-02	Cytokinetics, Inc.	Compounds, compositions and methods
GB0209995D0 (en)	2002-05-01	2002-06-12	Merck Sharp & Dohme	Therapeutic agents
WO2003093263A1 (en)	2002-05-02	2003-11-13	Neurogen Corporation	Substituted imidazole derivatives: gabaa receptor ligands
CA2484936A1 (en)	2002-05-08	2004-05-21	Neurogen Corporation	Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands
AU2003223786A1 (en)	2002-05-09	2003-11-11	Cytokinetics, Inc.	Compounds, methods and compositions
WO2003097053A1 (en)	2002-05-09	2003-11-27	Cytokinetics, Inc.	Compounds, compositions, and methods
WO2004026226A2 (en)	2002-05-10	2004-04-01	Cytokinetics, Inc.	Compounds, compositions and methods
ATE333455T1 (de)	2002-05-17	2006-08-15	Neurogen Corp	Substituierte, ringkondensierte imidazolderivate: gabaa-rezeptorliganden
AU2003231799A1 (en) *	2002-05-23	2003-12-12	Merck & Co., Inc.	Mitotic kinesin inhibitors
US7038048B2 (en)	2002-05-23	2006-05-02	Cytokinetics, Inc.	3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
AU2003236527A1 (en)	2002-06-14	2003-12-31	Cytokinetics, Inc.	Compounds, compositions, and methods
AU2003276005B2 (en)	2002-06-14	2009-01-15	Merck Sharp & Dohme Corp.	Mitotic kinesin inhibitors
PL374190A1 (en)	2002-06-14	2005-10-03	Merck & Co, Inc.	Mitotic kinesin inhibitors
AU2003247891A1 (en)	2002-07-08	2004-01-23	Merck & Co., Inc.	Mitotic kinesin binding site
AU2003252025A1 (en)	2002-07-17	2004-02-02	Cytokinetics, Inc.	Compounds, compositions, and methods
JP2006501201A (ja)	2002-07-23	2006-01-12	サイトキネティクス・インコーポレーテッド	化合物、組成物および方法
WO2004018058A2 (en)	2002-08-21	2004-03-04	Cytokinetics, Inc.	Compounds, compositions, and methods
WO2004024086A2 (en)	2002-09-13	2004-03-25	Cytokinetics, Inc.	Compounds, compositions and methods
CN100579579C (zh)	2002-10-01	2010-01-13	诺华疫苗和诊断公司	抗癌及抗感染性疾病组合物及其使用方法
DE60307499T2 (de)	2002-11-08	2007-02-01	Neurogen Corp., Branford	4-imidazol-1-ylmethylpyrimidinderivate als liganden für gabaa-rezeptoren
WO2004055008A1 (en) *	2002-12-13	2004-07-01	Smithkline Beecham Corporation	Compounds, compositions and methods
US20070149500A1 (en)	2003-01-17	2007-06-28	Han-Jie Zhou	Compounds, compositions, and methods
US20040186151A1 (en)	2003-02-12	2004-09-23	Mjalli Adnan M.M.	Substituted azole derivatives as therapeutic agents
WO2004100873A2 (en)	2003-05-07	2004-11-25	Cytokinetics, Inc.	Compounds, compositions, and methods
JP2007500746A (ja)	2003-05-15	2007-01-18	サイトキネティクス・インコーポレーテッド	化合物、組成物および方法
CN1809563A (zh)	2003-06-20	2006-07-26	希龙公司	吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药
WO2005041888A2 (en) *	2003-11-03	2005-05-12	Cytokinetics, Inc.	Pyrimidin-4-one compounds, compositions and methods
CN1922151A (zh) *	2004-02-12	2007-02-28	特兰斯泰克制药公司	取代的吡咯衍生物、组合物和使用方法
AU2005233576A1 (en) *	2004-04-06	2005-10-27	Novartis Vaccines And Diagnostics, Inc.	Mitotic kinesin inhibitors
JP2007532626A (ja)	2004-04-14	2007-11-15	ファイザー・インク	Ｈｉｖ治療用硫黄連結イミダゾール化合物
US7618981B2 (en)	2004-05-06	2009-11-17	Cytokinetics, Inc.	Imidazopyridinyl-benzamide anti-cancer agents
DK1753723T3 (da) *	2004-05-21	2008-10-20	Novartis Vaccines & Diagnostic	Substituerede quinolinderivater som mitotiske kinesininhibitorer
US7576221B2 (en) *	2004-06-18	2009-08-18	Novartis Vaccines And Diagnostics, Inc.	Substituted imidazole derivatives
JP2008517057A (ja) *	2004-10-19	2008-05-22	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	インドールおよびベンゾイミダゾール誘導体
TW200800951A (en) *	2005-08-09	2008-01-01	Novartis Ag	Substituted imidazole compounds as KSP inhibitors
MX2009005071A (es) *	2006-11-13	2009-05-25	Novartis Ag	Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.

2008
- 2008-01-03 US US11/969,164 patent/US7820646B2/en not_active Expired - Fee Related
- 2008-01-03 KR KR1020097016289A patent/KR20090097210A/ko not_active Application Discontinuation
- 2008-01-03 CN CN200880007148A patent/CN101622247A/zh active Pending
- 2008-01-03 GE GEAP200811346A patent/GEP20125415B/en unknown
- 2008-01-03 MX MX2009007260A patent/MX2009007260A/es not_active Application Discontinuation
- 2008-01-03 CA CA002674318A patent/CA2674318A1/en not_active Abandoned
- 2008-01-03 AU AU2008205169A patent/AU2008205169B2/en not_active Ceased
- 2008-01-03 EP EP08705667A patent/EP2106399A2/en not_active Withdrawn
- 2008-01-03 JP JP2009544977A patent/JP2010515687A/ja active Pending
- 2008-01-03 WO PCT/US2008/050149 patent/WO2008086122A2/en active Application Filing
- 2008-01-03 EA EA200900924A patent/EA200900924A1/ru unknown
- 2008-01-03 BR BRPI0806264-1A patent/BRPI0806264A2/pt not_active IP Right Cessation
- 2008-01-03 NZ NZ577727A patent/NZ577727A/en not_active IP Right Cessation
- 2008-01-04 CL CL200800029A patent/CL2008000029A1/es unknown
- 2008-01-04 TW TW097100432A patent/TW200836722A/zh unknown
- 2008-01-04 AR ARP080100042A patent/AR064760A1/es not_active Application Discontinuation
- 2008-01-04 PE PE2008000091A patent/PE20081850A1/es not_active Application Discontinuation
- 2008-03-01 UA UAA200906929A patent/UA97821C2/ru unknown
2009
- 2009-06-15 ZA ZA200904175A patent/ZA200904175B/xx unknown
- 2009-06-19 CR CR10879A patent/CR10879A/es unknown
- 2009-06-30 MA MA32061A patent/MA31080B1/fr unknown
- 2009-07-02 CO CO09068496A patent/CO6561828A2/es not_active Application Discontinuation
- 2009-07-02 NI NI200900134A patent/NI200900134A/es unknown
- 2009-07-02 DO DO2009000169A patent/DOP2009000169A/es unknown
- 2009-07-03 HN HN2009001262A patent/HN2009001262A/es unknown
- 2009-07-03 SV SV2009003325A patent/SV2009003325A/es not_active Application Discontinuation
- 2009-07-03 EC EC2009009485A patent/ECSP099485A/es unknown
- 2009-07-03 TN TNP2009000287A patent/TN2009000287A1/fr unknown
- 2009-07-03 GT GT200900192A patent/GT200900192A/es unknown
- 2009-07-23 SM SM200900065T patent/SMP200900065B/it unknown
2010
- 2010-09-15 US US12/882,473 patent/US20110003791A1/en not_active Abandoned
2012
- 2012-04-03 US US13/438,569 patent/US20120189623A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA200900924A1 (ru)	2009-12-30
MA31080B1 (fr)	2010-01-04
SMAP200900065A (it)	2009-09-07
NI200900134A (es)	2010-07-05
US7820646B2 (en)	2010-10-26
WO2008086122A2 (en)	2008-07-17
SMP200900065B (it)	2010-09-10
BRPI0806264A2 (pt)	2011-08-30
HN2009001262A (es)	2012-01-09
CA2674318A1 (en)	2008-07-17
ZA200904175B (en)	2010-04-28
TW200836722A (en)	2008-09-16
MX2009007260A (es)	2009-07-10
WO2008086122A3 (en)	2008-10-16
DOP2009000169A (es)	2009-08-31
TN2009000287A1 (en)	2010-12-31
GEP20125415B (en)	2012-03-12
CN101622247A (zh)	2010-01-06
ECSP099485A (es)	2009-08-28
US20080207589A1 (en)	2008-08-28
PE20081850A1 (es)	2009-02-05
CO6561828A2 (es)	2012-11-15
US20120189623A1 (en)	2012-07-26
CR10879A (es)	2009-08-05
JP2010515687A (ja)	2010-05-13
KR20090097210A (ko)	2009-09-15
UA97821C2 (en)	2012-03-26
AU2008205169A1 (en)	2008-07-17
NZ577727A (en)	2012-03-30
AU2008205169B2 (en)	2012-02-02
EP2106399A2 (en)	2009-10-07
AR064760A1 (es)	2009-04-22
GT200900192A (es)	2010-06-24
US20110003791A1 (en)	2011-01-06
SV2009003325A (es)	2011-08-09

Publication	Publication Date	Title
CL2008000029A1 (es)	2008-04-04	Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007003212A1 (es)	2008-06-27	Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer.
CL2008000197A1 (es)	2008-08-01	Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2008002319A1 (es)	2009-01-02	Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2008000754A1 (es)	2008-10-24	Compuesto derivado de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar cancer y trastornos hiperproliferativos.
CL2007003226A1 (es)	2008-02-08	Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
CL2007002316A1 (es)	2008-02-01	Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
CL2008001201A1 (es)	2008-08-08	Compuestos derivados de imidazol, triazol y/o piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension o insuficiencia cardiaca.
CL2011000134A1 (es)	2011-07-08	Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer.
CL2007002021A1 (es)	2008-02-08	Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias.
CL2008001372A1 (es)	2008-12-05	Compuestos derivados de pirazol sustituidos con heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos hiperproliferativos y enfermedades relacionadas con angiogenesis.
CL2008000794A1 (es)	2008-05-30	Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
CL2008001323A1 (es)	2009-05-29	Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2012003415A1 (es)	2013-08-09	Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CR20140544A (es)	2015-01-12	Compuestos para inhibir la progresión mitotica
CL2008001273A1 (es)	2008-09-22	Compuestos derivados de heterociclos, inhibidores de proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la inflamacion, enfermedad cardiovascular, asma
CL2008000793A1 (es)	2008-05-30	Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
BRPI0818804A2 (pt)	2015-04-22	Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
CL2008000022A1 (es)	2008-05-16	Compuestos derivados de fenil-(4-fenil pirimidin-2-il)-aminas; composicion farmaceutica que comprende a dichos compuestos ; procedimiento de preparacion de dichos compuestos; y su uso en enfermedades inflamatorias, diabetes y cancer.
CL2008000703A1 (es)	2008-09-26	Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos.
CL2007001674A1 (es)	2008-01-18	Compuestos derivados de heterociclos, inhibidores de aspartil proteasa; composicion farmaceutica que los comprende;y su uso para tratar enfermedades cardiovasculares,cognitivas y neurodegenerativas.
CL2007002916A1 (es)	2008-04-18	Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
CL2007002107A1 (es)	2008-06-06	Compuestos derivados de bencil piperidin-1-il amina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, ateroesclerosis, vasculopatia periferica, dislipidemia, entre otras enfermedades.